Renalytix Plc
RENXF
$0.091
-$0.039-30.00%
Weiss Ratings | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D- | |||
Reward Grade | E | |||
Rating Factors | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Fair | |||
Efficiency Index | Very Weak | |||
Solvency Index | Weak | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.95 | |||
Price History | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 0.00% | |||
30-Day Total Return | 13.75% | |||
60-Day Total Return | 13.75% | |||
90-Day Total Return | -43.13% | |||
Year to Date Total Return | 13.75% | |||
1-Year Total Return | -85.35% | |||
2-Year Total Return | -94.58% | |||
3-Year Total Return | -98.72% | |||
5-Year Total Return | -96.82% | |||
52-Week High % Change | -73.24% | |||
52-Week Low % Change | 13.75% | |||
Price | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $0.34 | |||
52-Week Low Price | $0.08 | |||
52-Week Low Price (Date) | Dec 03, 2024 | |||
52-Week High Price (Date) | May 07, 2024 | |||
Valuation | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 37.61M | |||
Enterprise Value | 44.72M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.27 | |||
Earnings Per Share Growth | -47.86% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 4.10 | |||
Price/Book (Q) | -1.33 | |||
Enterprise Value/Revenue (TTM) | 21.31 | |||
Price | $0.09 | |||
Enterprise Value/EBITDA (TTM) | -2.11 | |||
Enterprise Value/EBIT | -2.08 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 105.70M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 646 397 3970 | |||
Address | 1460 Broadway New York, NY 10036 | |||
Website | renalytix.com | |||
Country | United States | |||
Year Founded | 2018 | |||
Profitability | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -1,024.14% | |||
Profit Margin | -1,191.75% | |||
Management Effectiveness | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -123.74% | |||
Return on Equity | -- | |||
Income Statement | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 2.35M | |||
Total Revenue (TTM) | 2.35M | |||
Revenue Per Share | $0.02 | |||
Gross Profit (TTM) | 299.00K | |||
EBITDA (TTM) | -23.79M | |||
EBIT (TTM) | -24.09M | |||
Net Income (TTM) | -28.03M | |||
Net Income Avl. to Common (TTM) | -28.03M | |||
Total Revenue Growth (Q YOY) | 13.73% | |||
Earnings Growth (Q YOY) | 53.44% | |||
EPS Diluted (TTM) | -0.27 | |||
EPS Diluted Growth (Q YOY) | 59.36% | |||
Balance Sheet | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 909.00K | |||
Cash Per Share (Q) | $0.01 | |||
Total Current Assets (Q) | 2.88M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | -11.32M | |||
Current Ratio (Q) | 0.240 | |||
Book Value Per Share (Q) | -$0.07 | |||
Total Assets (Q) | 4.79M | |||
Total Current Liabilities (Q) | 12.01M | |||
Total Debt (Q) | 8.25M | |||
Total Liabilities (Q) | 16.11M | |||
Total Common Equity (Q) | -11.32M | |||
Cash Flow | RENXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -4.00K | |||
Cash from Financing (TTM) | 11.34M | |||
Net Change in Cash (TTM) | -12.98M | |||
Levered Free Cash Flow (TTM) | -15.33M | |||
Cash from Operations (TTM) | -24.44M | |||